fianlimab,cemiplimab
sanofi,regeneron
['fianlimab', 'cemiplimab', 'melanoma']
 presents on data with cemiplimab + fianlimab in #melanoma at #asco23. somewhat heterogeneous groups but an impressive response rate in group with prior pd-1 exposure in (neo)adjuvant setting. small numbers, but seems like an active combination worthy of more study. 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.